Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) shares traded 4.15% higher at $0.35 on Wall Street last session.
In accordance with the data, 1 analysts cover Aridis Pharmaceuticals Inc. (NASDAQ:ARDS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.00 and a low of $2.00, we find $2.00. Given the previous closing price of $0.34, this indicates a potential upside of 488.24 percent. ARDS stock price is now 49.91% away from the 50-day moving average and -44.90% away from the 200-day moving average. The market capitalization of the company currently stands at $11.61M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $2.00 as their price target over the next twelve months.
With the price target of $18, ROTH Capital recently initiated with Buy rating for Aridis Pharmaceuticals Inc. (NASDAQ: ARDS).
A total of 31.53% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ARDS stock. A new stake in Aridis Pharmaceuticals Inc. shares was purchased by SABBY MANAGEMENT, LLC during the first quarter worth $751,000. VONTOBEL HOLDING LTD. invested $18,000 in shares of ARDS during the first quarter. In the first quarter, PRUDENTIAL FINANCIAL INC acquired a new stake in Aridis Pharmaceuticals Inc. valued at approximately $13,000. ACADIAN ASSET MANAGEMENT LLC acquired a new stake in ARDS for approximately $13,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP purchased a new stake in ARDS valued at around $8,000 in the second quarter. In total, there are 23 active investors with 10.20% ownership of the company’s stock.
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) opened at $0.3010 on Thursday. During the past 12 months, Aridis Pharmaceuticals Inc. has had a low of $0.15 and a high of $2.77. The fifty day moving average price for ARDS is $0.2372 and a two-hundred day moving average price translates $0.6328 for the stock.
The latest earnings results from Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.6, missing analysts’ expectations of -$0.41 by -0.19. This compares to -$0.44 EPS in the same period last year. The company reported revenue of $1.08 million for the quarter, compared to $1.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -8.85 percent.
Aridis Pharmaceuticals Inc.(ARDS) Company Profile
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
